Treatment of Hypertensive Atherosclerotic Cardiovascular Disease
For patients with hypertension and atherosclerotic cardiovascular disease, initiate combination therapy with a RAS blocker (ACE inhibitor or ARB) plus a dihydropyridine calcium channel blocker or thiazide diuretic, targeting blood pressure to 120-129/80 mmHg systolic, while adding statin therapy to achieve LDL-C <55 mg/dL. 1, 2
Blood Pressure Targets
The most recent 2024 ESC guidelines establish a systolic BP target of 120-129 mmHg for most adults with treated hypertension, provided treatment is well tolerated 1. This represents a significant shift from older targets. For patients with atherosclerotic disease specifically, aim for <130/80 mmHg at minimum, with consideration for <120/80 mmHg 3, 2.
Critical caveat: In patients with elevated diastolic BP who have coronary artery disease and evidence of myocardial ischemia, lower BP slowly and avoid dropping diastolic BP below 60 mmHg, especially in patients with diabetes or age >60 years 3. Wide pulse pressures in older patients may result in very low diastolic values when lowering systolic BP—monitor carefully for myocardial ischemia and worsening symptoms.
Pharmacological Strategy
Initial Therapy
Start with combination therapy for most patients with confirmed hypertension (BP ≥140/90 mmHg) 1. The preferred combinations are:
- RAS blocker (ACE inhibitor OR ARB) + dihydropyridine calcium channel blocker
- RAS blocker + thiazide/thiazide-like diuretic (chlorthalidone or indapamide)
Use fixed-dose single-pill combinations to improve adherence 1.
Escalation Protocol
If BP remains uncontrolled on two drugs:
- Escalate to three-drug combination: RAS blocker + dihydropyridine CCB + thiazide/thiazide-like diuretic, preferably as single-pill combination 1
For resistant hypertension:
- Add aldosterone receptor antagonist (spironolactone) to first-line therapy 4
Beta-Blockers
Add beta-blockers when compelling indications exist: post-myocardial infarction, angina, heart failure with reduced ejection fraction, or heart rate control 1. Beta-blockers are inferior to other drug classes for reducing stroke, infarction, and mortality when used solely for hypertension 4, so they should not be first-line unless these specific indications are present.
Drugs to Avoid
Never use in atherosclerotic cardiovascular disease with hypertension:
- Non-dihydropyridine calcium channel blockers (verapamil, diltiazem) - negative inotropic effects 3
- Clonidine and moxonidine - associated with increased mortality in heart failure 3
- Alpha-blockers (doxazosin) - increased heart failure risk 3
- Dual RAS blockade (ACE inhibitor + ARB together) - not recommended 1
Lipid Management
Atherosclerotic cardiovascular disease mandates aggressive lipid lowering:
Target LDL-C <55 mg/dL (<1.4 mmol/L) for very high-risk patients with established atherosclerotic disease 2. This is non-negotiable for secondary prevention.
- Statins remain first-line with consistent evidence for reducing major adverse cardiovascular events, myocardial infarction, stroke, and all-cause mortality 5
- Consider nonstatin therapies (ezetimibe, PCSK9 inhibitors) if statin intolerance or inadequate LDL-C reduction 5
Lifestyle Modifications
Implement the S-ABCDE mnemonic 6:
- Sodium restriction (<2g/day)
- Regular exercise (closely monitored program) 3
- Weight loss if overweight
- Mediterranean diet with 5 portions vegetables/fruits daily 2
- Smoking cessation
- Sleep disturbance management 2
These are Class I recommendations and should be initiated immediately alongside pharmacotherapy 3.
Monitoring Strategy
Use home blood pressure monitoring (HBPM) with the 722 protocol: duplicate readings per occasion, twice daily, over seven consecutive days 6. This is more reliable than office measurements and better correlates with organ damage and cardiovascular events.
Target hierarchy 6:
- Achieve HBPM target first
- Ensure hypertension-mediated organ damage remains stable or regresses
- If targets not met, arrange ambulatory BP monitoring to guide adjustment
Special Considerations for Heart Failure
If systolic heart failure coexists:
- Use diuretics + ACE inhibitor/ARB + beta-blocker + aldosterone antagonist 3
- Target BP <130/80 mmHg, consider <120/80 mmHg 3
- In Black patients with NYHA class III-IV, add hydralazine/isosorbide dinitrate 3
Maintain BP-lowering treatment lifelong, even beyond age 85 years, if well tolerated 1.